Document:

EX-10.13

 Exhibit 10.13 

VERRICA PHARMACEUTICALS INC. 

ADVISOR AGREEMENT 
 This
Advisor Agreement (“Agreement”) is made and entered into as of August 7th 2014 (the “Effective Date”), by and between Verrica Pharmaceuticals Inc., a Delaware
corporation (the “Company”), and Glenn Oclassen (“Advisor”). The Company desires to retain Advisor as an independent contractor to perform certain advisory services for the Company, and Advisor is willing to perform
such services, on terms set forth more fully below. In consideration of the mutual promises contained herein, and other good and valuable consideration, the parties agree as follows: 

1. SERVICES AND COMPENSATION 

(a) Services. Advisor agrees to (i) advise the Company on general strategic business and technical matters in line with the
responsibilities set forth in Appendix A, (ii) use his/her best efforts to meet with the Company’s Board of Directors and/or management in person once ever calendar quarter, and (iii) collaborate and provide advice and assistance to
the Company as is mutually agreed by the parties (collectively, the “Services”). 
 (b) Compensation. Subject to the
approval of the Company’s Board of Directors, Advisor will be granted a nonstatutory stock option under the Company’s 2014 Equity Incentive Plan to purchase up to 142,132 shares of the Company’s Common Stock. 1/24th of the aggregate number of shares subject to such option shall vest on the corresponding day of each month after July 30th 2014 subject to
Advisor continuing to be a service provider to the Company through each such date. The option will be evidenced by and subject to all of the terms of the Company’s form of stock option agreement. 

2. CONFIDENTIALITY 

(a) Definition. “Confidential Information” means any Company proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, customers, customer lists, databases, markets, software, developments, inventions, processes, formulas, technology, designs,
drawings, engineering, hardware configuration information, marketing, finances or other business information disclosed by the Company either directly or indirectly in writing, orally or by drawings or inspection of equipment. 

(b) Non-Use and Non-Disclosure. Advisor will not, during
or subsequent to the term of this Agreement, use the Company’s Confidential Information for any purpose whatsoever other than the performance of the Services on behalf of the Company or disclose the Company’s Confidential Information to
any third party. It is understood that said Confidential Information shall remain the sole property of the Company. Advisor further agrees to take all reasonable precautions to prevent any unauthorized disclosure of such Confidential Information
including, but not limited to, having each employee of Advisor, if any, with access to any Confidential Information, execute a nondisclosure agreement containing provisions in the Company’s favor identical to Sections 2, 3 and 4 of this
Agreement. Confidential Information does not include information which (i) is known to Advisor at the time of disclosure to Advisor by the Company as evidenced by written records of Advisor, (ii) has become publicly known and made
generally available through no wrongful act of Advisor, or (iii) has been rightfully received by Advisor from a third party who is authorized to make such disclosure. 

 (c) Other Employer’s Confidential Information. Advisor agrees that
Advisor will not, during the term of this Agreement, improperly use or disclose any proprietary information or trade secrets of any former or current employer or other person or entity with which Advisor has an agreement or duty to keep in
confidence information acquired by Advisor, if any, and that Advisor will not bring onto the premises of the Company any unpublished document or proprietary information belonging to such employer, person or entity unless consented to in writing by
such employer, person or entity. Advisor will indemnify the Company and hold it harmless from and against all claims, liabilities, damages and expenses, including reasonable attorneys fees and costs of suit, arising out of or in connection with any
violation or claimed violation of a third party’s rights resulting in whole or in part from the Company’s use of the work product of Advisor under this Agreement. 

(d) Third Party Confidential Information. Advisor recognizes that the Company has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Advisor agrees that Advisor owes the Company and
such third parties, during the term of this Agreement and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as
necessary in carrying out the Services for the Company consistent with the Company’s agreement with such third party. 
 (e) Return
of Materials. Upon the termination of this Agreement, or upon Company’s earlier request, Advisor will deliver to the Company all of the Company’s property or Confidential Information that Advisor may have in Advisor’s possession
or control. 
 3. OWNERSHIP 

(a) Assignment. Advisor agrees that all copyrightable material, notes, records, drawings, designs, inventions, improvements,
developments, discoveries and trade secrets (collectively, “Inventions”) conceived, made or discovered by Advisor, solely or in collaboration with others, during the period of this Agreement which relate in any manner to the
business of the Company that Advisor may be directed to undertake, investigate or experiment with, or which Advisor may become associated with in work, investigation or experimentation in the line of business of Company in performing the Services
hereunder, are the sole property of the Company. Advisor further agrees to assign (or cause to be assigned) and does hereby assign fully to the Company all Inventions and any copyrights, patents, mask work rights or other intellectual property
rights relating thereto. 
 (b) Further Assurances. Advisor agrees to assist Company, or its designee, at the Company’s expense,
in every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company of all
pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in order to
assign and convey to the Company, its successors, assigns and nominees the sole and exclusive right, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto.
Advisor further agrees that Advisor’s obligation to execute or cause to be executed, when it is in Advisor’s power to do so, any such instrument or papers shall continue after the termination of this Agreement. 

  
 -2- 

 (c) Pre-Existing Materials. Advisor agrees that if
in the course of performing the Services, Advisor incorporates into any Invention developed hereunder any invention, improvement, development, concept, discovery or other proprietary information owned by Advisor or in which Advisor has an interest,
(i) Advisor shall inform Company in writing before incorporating such invention, improvement, development, concept, discovery or other proprietary information into any Invention; and (ii) the Company is hereby granted and shall have a
nonexclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, use and sell such item as part of or in connection with such Invention. Advisor shall not incorporate any invention, improvement, development, concept,
discovery or other proprietary information owned by any third party into any Invention without Company’s prior written permission. 

(d) Attorney in Fact. Advisor agrees that if the Company is unable because of Advisor’s unavailability, dissolution, mental or
physical incapacity, or for any other reason, to secure Advisor’s signature to apply for or to pursue any application for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to the
Company above, then Advisor hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Advisor’s agent and attorney in fact, to act for and in Advisor’s behalf and stead to execute and file any
such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright and mask work registrations thereon with the same legal force and effect as if executed by Advisor. 

4. CONFLICTING OBLIGATIONS 

Advisor certifies that Advisor has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, or
that would preclude Advisor from complying with the provisions hereof, and further certifies that Advisor will not enter into any such conflicting agreement during the term of this Agreement. 

5. TERM AND TERMINATION 

(a) Term. This Agreement will commence on the date first written above and will continue until the earlier of (i) final completion
of the Services or (ii) termination as provided below. 
 (b) Termination. Advisor and the Company may terminate this Agreement
at will. Any such notice of termination by a party shall be addressed to the other party at the address for such other party shown below or such other address as such other party may notify the terminating party of from time to time in writing and
shall be deemed given upon delivery if personally delivered, or forty-eight (48) hours after deposited in the United States mail, postage prepaid, registered or certified mail, return receipt requested. 

(c) Survival. Upon such termination all rights and duties of the parties toward each other shall cease except Section(s) 2
(Confidentiality), 3 (Ownership) and 7 (Independent Contractor) shall survive termination of this Agreement. 

  
 -3- 

 6. ASSIGNMENT 

Neither this Agreement nor any right hereunder or interest herein may be assigned or transferred by Advisor without the express written consent
of the Company. 
 7. INDEPENDENT CONTRACTOR 

It is the express intention of the parties that Advisor is an independent contractor. Nothing in this Agreement shall in any way be construed
to constitute Advisor as an agent, employee or representative of the Company, but Advisor shall perform the Services hereunder as an independent contractor. Advisor agrees to furnish (or reimburse the Company for) all tools and materials necessary
to accomplish this contract, and shall incur all expenses associated with performance, except as expressly agreed upon by the Company. Advisor acknowledges and agrees that Advisor is obligated to report as income all compensation received by Advisor
pursuant to this Agreement, and Advisor agrees to and acknowledges the obligation to pay all self-employment and other taxes thereon. Advisor further agrees to indemnify and hold harmless the Company and its directors, officers, and employees from
and against all taxes, losses, damages, liabilities, costs arid expenses, including attorney’s fees and other legal expenses, arising directly or indirectly from (i) any negligent, reckless or intentionally wrongful act of Advisor or
Advisor’s assistants, employees or agents, including, but not limited to, any damage to or disclosure of any Company Confidential Information (ii) a determination by a court or agency that the Advisor is not an independent contractor, or
(iii) any breach by the Advisor or Advisor’s assistants, employees or agents of any of the covenants contained in this Agreement. 

8. ARBITRATION AND EQUITABLE RELIEF 

(a) Disputes. Except as provided in Section 8(d) below, the Company and Advisor agree that any dispute or controversy arising out
of, relating to or in connection with the interpretation, validity, construction, performance, breach or termination of this Agreement shall be settled by binding arbitration to be held in Santa Clara County, California, in accordance with the
Commercial Arbitration Rules, supplemented by the Supplemental Procedures for Large Complex Disputes, of the American Arbitration Association as then in effect (the “Rules”). The arbitrator may grant injunctions or other relief in
such dispute or controversy. The decision of the arbitrator shall be final, conclusive and binding on the parties to the arbitration. Judgment may be entered on the arbitrator’s decision in any court of competent jurisdiction. 

(b) Consent to Personal Jurisdiction. The arbitrator(s) shall apply California law to the merits of any dispute or claim, without
reference to conflicts of law rules. Advisor hereby consents to the personal jurisdiction of the state and federal courts located in California for any action or proceeding arising from or relating to this Agreement or relating to any arbitration in
which the parties are participants. 
 (c) Costs. The Company and Advisor shall each pay
one-half of the costs and expenses of such arbitration, and each shall separately pay its counsel fees and expenses unless otherwise required by law. 

(d) Equitable Relief. The parties may apply to any court of competent jurisdiction for a temporary restraining order, preliminary
injunction, or other interim or conservatory relief, as necessary, without breach of this arbitration agreement and without abridgment of the powers of the arbitrator. 

  
 -4- 

 (e) Acknowledgment. ADVISOR HAS READ AND UNDERSTANDS SECTION 8, WHICH DISCUSSES
ARBITRATION. ADVISOR UNDERSTANDS THAT BY SIGNING THIS AGREEMENT, ADVISOR AGREES TO SUBMIT ANY CLAIMS ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH THIS AGREEMENT, OR THE INTERPRETATION, VALIDITY, CONSTRUCTION, PERFORMANCE, BREACH OR TERMINATION
THEREOF, TO BINDING ARBITRATION, EXCEPT AS PROVIDED IN SECTION 8(d), AND THAT THIS ARBITRATION CLAUSE CONSTITUTES A WAIVER OF ADVISOR’S RIGHT TO A JURY TRIAL AND RELATES TO THE RESOLUTION OF ALL DISPUTES RELATING TO ALL ASPECTS OF THE
RELATIONSHIP BETWEEN THE PARTIES. 
 9. GOVERNING LAW 

This Agreement shall be governed by the internal substantive laws, but not the choice of law rules, of the State of California. 

10. ENTIRE AGREEMENT 

This Agreement constitutes the entire agreement of the parties and supersedes any prior agreements between them, whether written or oral, with
respect to the subject matter hereof. No waiver, alteration, or modification of any of the provisions of this Agreement shall be binding unless in writing and signed by duly authorized representatives of the parties hereto. 

11. ATTORNEY’S FEES 

In any court action at law or equity which is brought by one of the parties to enforce or interpret the provisions of this Agreement, the
prevailing party will be entitled to reasonable attorney’s fees, in addition to any other relief to which that party may be entitled. 

12. SEVERABILITY 

The invalidity or unenforceability of any provision of this Agreement, or any terms thereof, shall not affect the validity of this Agreement
as a whole, which shall at all times remain in full force and effect. 
 (Signature page follows) 

  
 -5- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first
above written. 
  

			
	ADVISOR
	
	 /s/ Glenn Oclassen

		
	Address:	 	
	
	  

	
	  

	
	VERRICA PHARMACEUTICALS INC.
		
	By:	 	 /s/ Matthew Davidson

	Name:	 	Matthew Davidson
	Title:	 	Chief Executive Officer
		
	Address:	 	
		 	XXX
		 	XXX

 APPENDIX A 

Glenn Oclassen 
 Upon expansion
of the Board of Directors, and at the request of the current board, Glenn Oclassen will serve as a board member for Verrica Pharmaceuticals Inc. At such time a separate agreement will be drafted defining the responsibilities of this position. The
compensation herein is inclusive of the current role as an advisor and the future role as a board member. 
 Advisor Responsibilities

  

	 	•	 	Helping to evaluate business opportunities 

  

	 	•	 	Helping to make strategic decisions 

  

	 	•	 	Networking – Making introductions and phone calls 

  

	 	•	 	Reviewing contracts and agreements 

  

	 	•	 	Participating in phone calls and meetings with key opinion leaders and regulatory authorities 

  

	 	•	 	Providing general insight and strategy regarding drug development 

  
 -2-EX-10.14

 Exhibit 10.14 

VERRICA PHARMACEUTICALS INC. 

AMENDED AND RESTATED RESTRICTED STOCK PURCHASE AGREEMENT 

This Amended and Restated Restricted Stock Purchase Agreement (the “Agreement”) is made as of December 2, 2015 by
and between Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Matthew Davidson (the “Purchaser”). 

WHEREAS, the Purchaser previously purchased from the Company and the Company previously issued and sold to the Purchaser an aggregate
of 6,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain Restricted Stock Purchase Agreement, dated as of
August 8, 2013, by and between the Company and the Purchaser (the “Prior Agreement”). 
 WHEREAS, the
Company and certain investors (the “Investors”) are parties to that certain Series A Preferred Stock Purchase Agreement, pursuant to which such Investors are purchasing shares of the Company’s Series A Preferred Stock.

 WHEREAS, the Company and the Purchaser desire to induce such Investors to purchase shares of Series A Preferred Stock pursuant to
the Series A Preferred Stock Purchase Agreement by entering into this Agreement, which shall amend and restate the Prior Agreement in its entirety, on the terms and conditions as set forth herein. 

NOW, THEREFORE, IT IS AGREED, In consideration of the mutual covenants and representations set forth below, and for good and valuable
consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the Company and the Purchaser agree as follows: 
 1.
Purchase and Sale of the Shares. 
 A. Subject to the terms and conditions of this Agreement, the Company sold to the Purchaser and
the Purchaser purchased from the Company at the Closing (as defined below) the Shares, at a price of $0.0001 per share (the “Purchase Price”), for an aggregate purchase price of $600.00. As additional consideration for the
Company’s agreement to sell the Shares, the Purchaser transferred and assigned to the Company (i) the business plan of the Company (the “Business Plan”) and (ii) any and all right, title and interest the
Purchaser had in the Company’s business and any Intellectual Property (as defined below) related to the Company’s business, as then conducted and as then contemplated to be conducted pursuant to the Business Plan or otherwise. For purposes
hereof, “Intellectual Property” means: (i) United States and foreign patents, trademarks, copyrights and mask works, registrations and applications therefor, and rights granted upon any reissue, division, continuation or
continuation-in-part thereof, (ii) trade secret rights arising out of the laws of any and all jurisdictions, (iii) ideas, inventions, concepts, technology,
software, methods, processes, drawings, illustrations, writings know-how, show-how, trade names, domain names, web addresses and web sites, and all rights therein and
thereto, (iv) any other intellectual property rights, whether or not registrable, and (v) licenses in or to any of the foregoing. Further, the Purchaser agrees to take all actions reasonably requested by the Company to assist the Company
in effecting the foregoing transfer and in establishing, perfecting, defending, enforcing and protecting the Company’s rights in any of the above transferred items, including without limitation assisting in the prosecution of any patent
applications included in or based upon the Intellectual Property. 

 B. To facilitate the investments by the Investors, the Purchaser agrees to allow the Company to
repurchase from the Purchaser 180,217 of the total number of Shares (the “Repurchased Shares”) effective on the date hereof at the Purchase Price for an aggregate purchase price of $18.03 at the Repurchase Closing (as defined
below). 
 2. Closings. 
 A. The
purchase and sale of the Shares occurred at a closing (the “Closing”) held on August 8, 2013. The Closing took place at the principal office of the Company. At the Closing, the Purchaser delivered the aggregate Purchase
Price set forth above to the Company by wire transfer, check or any other method of payment permissible under applicable law and approved by the Company’s board of directors (or any combination of such methods of payment). 

B. The purchase and sale of the Repurchased Shares shall occur at a closing (the “Repurchase Closing”) to be held on
the date first set forth above. The Closing will take place at the principal office of the Company or at such other place as shall be designated by the Company. At the Closing, the Company shall deliver the aggregate Purchase Price set forth above
to the Purchaser by wire transfer, check or any other method of payment permissible under applicable law and approved by the Company’s board of directors (or any combination of such methods of payment), and the Purchaser agrees to deliver to
the Company and/or the Escrow Agent (as defined below) a stock power and assignment separate from certificate to give effect to the Company’s repurchase of the Repurchase Shares at the Repurchase Closing. 

 

	3.	Repurchase Option. 

 A. Option. In the event the Purchaser ceases to be an
employee, consultant, advisor, officer or director of the Company (a “Service Provider”) for any or no reason, including, without limitation, by reason of the Purchaser’s death or disability (as defined in
Section 22(e)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), “Disability”), resignation or involuntary termination, the Company shall, from such time (as determined by the
Company in its discretion), have an irrevocable, exclusive option to repurchase (the “Repurchase Option”) any Shares which have not yet been released from the Repurchase Option (the “Unreleased
Shares”), at a price per share equal to the lesser of (x) the fair market value of the shares at the time the Repurchase Option is exercised, as determined by the Company’s board of directors and (y) the Purchase Price
(the “Repurchase Price”). The Company may exercise its Repurchase Option as to any or all of the Unreleased Shares at any time after the Purchaser ceases to be a Service Provider; provided, however, that without
requirement of further action on the part of either party hereto, the Repurchase Option shall be deemed to have been automatically exercised as to all Unreleased Shares at 5:00 p.m. (Pacific Time) as of the date that is 60 days following the date
the Purchaser ceases to be a Service Provider, unless the Company declines in writing to exercise its Repurchase Option prior to such time. 

  
 2 

 B. Exercise. If the Company decides not to exercise its Repurchase Option, it shall
notify the Purchaser in writing within 60 days of the date the Purchaser ceases to be a Service Provider. If the Repurchase Option is exercised or deemed exercised, within 90 days of the date the Purchaser ceases to be a Service Provider, the
Company shall deliver payment to the Purchaser, with a copy to the Escrow Agent (as defined in Section 8 hereof), by any of the following methods, in the Company’s sole discretion: (i) delivering to the Purchaser
or the Purchaser’s executor a check in the amount of the aggregate Repurchase Price, (ii) canceling an amount of the Purchaser’s indebtedness to the Company equal to the aggregate Repurchase Price, or (in) any combination of
(i) and (ii) such that the combined payment and cancellation of indebtedness equals the aggregate Repurchase Price. 
 C. Rights
upon Exercise. In the event that the Repurchase Option is exercised or deemed exercised, the sole right and remedy of the Purchaser thereafter shall be to receive the Repurchase Price, and in no case shall the Purchaser have any claim of
ownership as to any of the Unreleased Shares. 
 D. Assignability. The Company in its sole discretion may assign all or part of
the Repurchase Option to one or more employees, officers, directors or stockholders of the Company or other persons or organizations. 
 4. Release of
Shares from Repurchase Option; Vesting. 
 A. Vesting. As of the date hereof, the Purchase and the Company agree that
4,364,837 of the total number of Shares are released from the Repurchase Option. So long as the Purchaser’s continuous status as a Service Provider has not yet terminated in each such instance, 1,454,946 of the remaining Shares (subject to
appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification, or similar event affecting the Company’s stock) shall be released from the Repurchase Option on the earliest to occur of (i) the
Company’s consummation of a Change of Control, (ii) the U.S. Food and Drug Administration’s approval of the Company’s new drug application for cantharidin or a cantharidin derivative, (iii) the Company’s commencement of
commercial sale of Products and (iv) a Covered Termination; provided, that, in the case of clause (iv) of this sentence, the Purchaser delivers to the Company a general release of all claims against the Company and its affiliates in
a form acceptable to the Company that becomes effective and irrevocable within 60 days, or such shorter period of time specified by the Company, following such Covered Termination. 

B. “Change of Control” Definition. For purposes of this Agreement, a “Change of Control” means
(i) a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or substantially all of the Company’s assets, or (ii) a merger or consolidation of the Company with or into any other
corporation or other entity or person or any other transaction or a series of related transactions, including the sale by the Company of new shares of its capital stock or a transfer of existing shares of capital stock of the Company, the result of
which is that a third party that is not an affiliate of the Company or its stockholders (or a group of third parties not affiliated with the Company or its stockholders) immediately prior to such transaction acquires or holds capital stock of the
Company representing a majority of the Company’s outstanding voting power immediately following such transaction; provided, that the following events shall not constitute a “Change in Control”: (A) a transaction (other than a
sale of all or substantially all of the Company’s assets) in which the holders of the voting securities of the Company immediately prior to the merger, consolidation or other transaction hold, directly or 

  
 3 

 
indirectly, at least a majority of the voting securities in the successor corporation or its parent immediately after the merger, consolidation or other transaction; (B) a sale, lease,
exchange or other transaction in one transaction or a series of related transactions of all or substantially all of the Company’s assets to an affiliate of the Company; (C) an initial public offering of any of the Company’s
securities; (D) a reincorporation of the Company solely to change its jurisdiction; (E) a transaction undertaken for the primary purpose of creating a holding company that will be owned in substantially the same proportion by the persons
who held the Company’s securities immediately before such transaction; or (F) any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor or
indebtedness of the Company is cancelled or converted or a combination thereof. 
 C. “Cause” Definition. For
purposes of this Agreement, “Cause” shall mean: means the occurrence of any of the following events, as determined by the Board of Directors of the Company or a committee designated by the Board of Directors of the Company,
in its sole discretion: (i) Purchaser’s commission of any felony or any crime involving fraud, dishonesty, or moral turpitude under the laws of the United States or any state thereof; (ii) Purchaser’s attempted commission of, or
participation in, a fraud or act of material dishonesty against the Company; (iii) Purchaser’s intentional, material violation of any contract or agreement between Purchaser and the Company or of any statutory duty owed to the Company;
(iv) Purchaser’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) Purchaser’s gross misconduct. 

D. “Good Reason” Definition. For purposes of this Agreement, “Good Reason” shall mean
Purchaser’s resignation from all positions he then holds with the Company if (i) (A) there is a material diminution in Purchaser’s duties or responsibilities with the Company; provided, however, that a change in title
will not constitute Good Reason; (B) there is a material reduction of Purchaser’s base salary; or (C) Purchaser is required to relocate Purchaser’s primary work location to a facility or location that would increase
Purchaser’s one-way commute distance and is more than twenty-five (25) miles from Purchaser’s primary work location as of immediately prior to such change, (ii) Purchaser provides written
notice outlining such conditions, acts or omissions to the Company within thirty (30) days immediately following such material change or reduction, (iii) such material change or reduction is not remedied by the Company within thirty
(30) days following the Company’s receipt of such written notice and (iv) Purchaser’s resignation is effective not later than thirty (30) days after the expiration of such thirty (30) day cure period. 

E. Covered Termination. For purposes of this Agreement, “Covered Termination” means the termination of
Purchaser’s employment by the Company other than for Cause or by Purchaser for Good Reason. 
 F. Product. For purposes of
this Agreement, “Product” means a product that has cantharidin or a cantharidin derivative as its active pharmaceutical ingredient and that is approved by the U.S. Food and Drug Administration. 

G. Delivery of Released Shares. Subject to the provisions of Section 8, the Shares that have been
released from the Company’s Repurchase Option shall be delivered to the Purchaser at the Purchaser’s request. 

  
 4 

 5. Limitation on Payments. 

A. Payments Limitation. In the event that the severance and other benefits provided for in this Agreement or otherwise
payable to the Purchaser (i) constitute “parachute payments” within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the
“Excise Tax”), then the Purchaser’s benefits under this Agreement shall be either: 
  

	 	(1)	delivered in full, or 

  

	 	(2)	delivered as to such lesser extent which would result in no portion of such benefits being subject to the Excise Tax, 

whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by the
Purchaser on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code. Any reduction in payments
and/or benefits required by this Section 5 will occur in the following order: (1) reduction of cash payments; (2) reduction of vesting acceleration of equity awards; and (3) reduction of other benefits paid
or provided to the Purchaser. In the event that acceleration of vesting of equity awards is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant for the Purchaser’s equity awards. If two or
more equity awards are granted on the same date, each award will be reduced on a pro-rata basis. In no event will the Purchaser exercise any discretion with respect to the ordering of any reductions of
payments or benefits under this Section 5. 
 B. Determination. Unless the Company and the Purchaser
otherwise agree in writing, any determination required under this Section 5 shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination
shall be conclusive and binding upon the Purchaser and the Company for all purposes. For purposes of making the calculations required by this Section 5, the Accountants may make reasonable assumptions and approximations
concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999 of the Code. The Company and the Purchaser shall furnish to the Accountants such information and documents as
the Accountants may reasonably request in order to make a determination under this Section 5. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this
Section 5. 
 6. Restrictions on Transfer. 

A. Investment Representations and Legend Requirements. The Purchaser made the investment representations listed on Exhibit
A to the Company as of the date of the Prior Agreement and as of the date of the Closing as of the date of this Agreement and as of the date of the Closing, and agrees that such representations are incorporated into this Agreement by this reference,
such that the Company may rely on them in issuing the Shares. The Purchaser understands and agrees that the Company shall cause the legends set forth below, or substantially equivalent legends, to be placed upon any certificate(s) or book entry
positions evidencing ownership of the Shares, together with any other legends that may be required by the Company or by applicable state or federal securities laws: 

  
 5 

 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE
“ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER, A RIGHT OF FIRST REFUSAL, A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING AND A REPURCHASE OPTION HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE AMENDED AND RESTATED
RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL,
LOCK-UP PERIOD AND REPURCHASE OPTION ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 B.
Stop-Transfer Notices. The Purchaser agrees that to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the
Company transfers its own securities, it may make appropriate notations to the same effect in its own records. 
 C. Refusal to
Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to
accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 
 D.
Lock-Up Period. The Purchaser hereby agrees that the Purchaser shall not sell, offer, pledge, contract to sell, grant any option or contract to purchase, purchase any option or contract to sell,
grant any right or warrant to purchase, lend or otherwise transfer or encumber, directly or indirectly, any Shares or other securities of the Company, nor shall the Purchaser enter into any swap, hedging or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company, during the period from the filing of the first registration statement of the Company filed under the Securities Act of
1933, as amended (the “Securities Act”), that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the 

  
 6 

 
Securities Act through the end of the 180-day period following the effective date of such registration statement (or such other period as may be requested
by the Company or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4
or similar forms that may be promulgated in the future. The Purchaser further agrees, if so requested by the Company or any representative of its underwriters, to enter into such underwriter’s standard form of “lockup” or “market
standoff” agreement in a form satisfactory to the Company and such underwriter. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of any such restriction period.

 E. Unreleased Shares. No Unreleased Shares subject to the Repurchase Option contained in
Section 3 of this Agreement, nor any beneficial interest in such Shares, shall be sold, gifted, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by the Purchaser, other
than as expressly permitted or required by Section 3. 
 F. Released Shares. No Shares purchased
pursuant to this Agreement, nor any beneficial interest in such Shares, shall be sold, transferred, encumbered or otherwise disposed of in any way (whether by operation of law or otherwise) by the Purchaser or any subsequent transferee, other than
in compliance with the Company’s right of first refusal provisions contained in Section 7 of this Agreement. 
 7.
Company’s Right of First Refusal. Before any Shares acquired by the Purchaser pursuant to this Agreement (or any beneficial interest in such Shares) may be sold, transferred, encumbered or otherwise disposed of in any way
(whether by operation of law or otherwise) by the Purchaser or any subsequent transferee (each a “Holder”), such Holder must first offer such Shares or beneficial interest to the Company and/or its assignee(s) as follows:

 A. Notice of Proposed Transfer. The Holder shall deliver to the Company a written notice stating: (i) the
Holder’s bona fide intention to sell or otherwise transfer the Shares; (ii) the name of each proposed transferee; (iii) the number of Shares to be transferred to each proposed transferee; (iv) the bona fide cash price or other
consideration for which the Holder proposes to transfer the Shares; and (v) that by delivering the notice, the Holder offers all such Shares to the Company and/or its assignee(s) pursuant to this section and on the same terms described in the
notice. 
 B. Exercise of Right of First Refusal. At any time within 30 days after receipt of the Holder’s notice,
the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the proposed transferees, at the purchase price determined
in accordance with Section 7.C. 

  
 7 

 C. Purchase Price. The purchase price for the Shares purchased by the Company
and/or its assignee(s) under this section shall be the price listed in the Holder’s notice. If the price listed in the Holder’s notice includes consideration other than cash, the cash equivalent value of the
non-cash consideration shall be determined by the board of directors of the Company in its sole discretion. 

D. Payment. Payment of the purchase price shall be made, at the option of the Company and/or its
assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company and/or its assignee(s), or by any combination thereof within 30 days after receipt by the Company of the Holder’s
notice (or at such later date as is called for by such notice). 
 E. Holder’s Right to Transfer. If all of the
Shares proposed in the notice to be transferred to a given proposed transferee are not purchased by the Company and/or its assignee(s) as provided in this section, then the Holder may sell or otherwise transfer such Shares to that proposed
transferee; provided that: (i) the transfer is made only on the terms provided for in the notice, with the exception of the purchase price, which may be either the price listed in the notice or any higher price; (ii) such transfer is
consummated within 60 days after the date the notice is delivered to the Company; (iii) the transfer is effected in accordance with any applicable securities laws, and if requested by the Company, the Holder shall have delivered an opinion of
counsel acceptable to the Company to that effect; and (iv) the proposed transferee agrees in writing to receive and hold the Shares so transferred subject to all of the provisions of this Agreement, including but not limited to this section,
and there shall be no further transfer of such Shares except in accordance with the terms of this section. If any Shares described in a notice are not transferred to the proposed transferee within the period provided above, then before any such
Shares may be transferred, a new notice shall be given to the Company, and the Company and/or its assignees shall again be offered the right of first refusal described in this section. 

F. Involuntary Transfers. Subject to the other provisions of this Section 7, in the event, at
any time after the date of this Agreement, of any transfer by operation of law or other involuntary transfer (including, but not limited to, transfers by operation of law or other involuntary transfers in connection with a divorce, dissolution,
legal separation or annulment) of all or a portion of the Shares by the record holder thereof that does not occur in accordance with the other provisions of this Section 7, the Company shall have the right to purchase all
of the Shares transferred at the greater of the purchase price paid by the Purchaser pursuant to this Agreement or the fair market value of the Shares on the date of transfer (as determined by the board of directors of the Company). Upon such a
transfer, the persons transferring or acquiring the Shares shall promptly notify the Secretary of the Company in writing of such transfer. The right to purchase such Shares shall be provided to the Company for a period of 30 days following receipt
by the Company of written notice of the transfer. 
 G. Exception for Certain Family Transfers. Notwithstanding anything
to the contrary contained elsewhere in this section, the transfer of any or all of the Shares during the Holder’s lifetime (except in connection with a divorce, dissolution, legal separation or annulment), or on the Holder’s death by will
or intestacy, to (i) the Holder’s spouse or domestic partner; (ii) the Holder’s lineal descendants or antecedents, siblings, aunts, uncles, cousins, 

  
 8 

 
nieces and nephews (including adoptive relationships and step relationships), and their spouses or domestic partners; (iii) the lineal descendants or antecedents, siblings, cousins, aunts,
uncles, nieces and nephews of Holder’s spouse or domestic partner (including adoptive relationships and step relationships), and their spouses or domestic partners; and (iv) a trust or other similar estate planning vehicle for the benefit
of the Holder or any such person, shall be exempt from the provisions of this section; provided that, in each such case, the transferee agrees in writing to receive and hold the Shares so transferred subject to all of the provisions of this
Agreement, including but not limited to this section, and there shall be no further transfer of such Shares except in accordance with the terms of this section; and provided further, that without the prior written consent of the Company,
which may be withheld in the sole discretion of the Company, no more than three transfers may be made pursuant to this section, including all transfers by the Holder and all transfers by any transferee. For purposes of this Agreement, a person will
be deemed to be a “domestic partner” of another person if the two persons (1) reside in the same residence and plan to do so indefinitely, (2) have resided together for at least one year, (3) are each at least 18 years of
age and mentally competent to consent to contract, (4) are not blood relatives any closer than would prohibit legal marriage in the state in which they reside, (5) are financially interdependent, as demonstrated to the reasonable
satisfaction of the Company and (6) have each been the sole spouse equivalent of the other for the year prior to the transfer and plan to remain so indefinitely; provided that a person will not be considered a domestic partner if he or she is
married to another person or has any other spouse equivalent. 
 H. Termination of Right of First Refusal. The rights contained
in this section shall terminate as to all Shares purchased hereunder upon the earlier of: (i) the closing date of the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared
effective by the Securities and Exchange Commission under the Securities Act, and (ii) the closing date of a Change of Control pursuant to which the holders of the outstanding voting securities of the Company receive securities of a class
registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. 
 8. Escrow. 

A. Deposit. As security for the faithful performance of this Agreement, the Purchaser agrees, immediately upon receipt of
any certificate(s) evidencing the Shares, to deliver such certificate(s) together with a stock power in the form of Exhibit B attached to this Agreement, executed by the Purchaser and by the Purchaser’s spouse, if any (with the date and number
of Shares left blank) in the form of Exhibit E attached hereto, to the Secretary of the Company or to another designee of the Company (the “Escrow Agent”). These documents shall be held by the Escrow Agent pursuant to the
Amended and Restated Joint Escrow Instructions of the Company and the Purchaser set forth in Exhibit C attached to this Agreement, which instructions are incorporated into this Agreement by this reference, and which instructions were delivered to
the Escrow Agent after the Closing. 
 B. Rights in Escrow Shares. Subject to the terms hereof, the Purchaser shall have all
the rights of a stockholder with respect to such Shares while they are held in escrow, including without limitation, the right to vote the Shares. If, from time to time during the term of the Company’s Repurchase Option, there is (i) any
stock dividend, stock split or other change in the Shares, (ii) any dividend of cash or other property on the Shares, or (iii) any merger or sale of all 

  
 9 

 
or substantially all of the assets or other acquisition of the Company, any and all new, substituted or additional securities or cash or other consideration to which the Purchaser is entitled by
reason of the Purchaser’s ownership of the Shares shall immediately become subject to this escrow, deposited with the Escrow Agent and included thereafter as “Shares” for purposes of this Agreement and the Company’s
Repurchase Option. 
 9. Tax Consequences. The Purchaser has reviewed with the Purchaser’s own tax advisors the federal, state, local and
foreign tax consequences of this investment and the transactions contemplated by this Agreement. The Purchaser is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. The Purchaser
understands that the Purchaser (and not the Company) shall be responsible for any tax liability that may arise as a result of the transactions contemplated by this Agreement. The Purchaser understands that Section 83 of the Code, taxes as
ordinary income the difference between the purchase price for the Shares and the fair market value of the Shares as of the date any restrictions on the Shares lapse. In this context, “restriction” includes the right of the
Company to buy back the Shares pursuant to the Repurchase Option. The Purchaser elected to be taxed at the time the Shares are purchased rather than when and as the Repurchase Option expires by filing an election under Section 83(b) of the Code
with the IRS within 30 days from the date of purchase of the Shares at the Closing. THE FORM FOR MAKING THIS SECTION 83(B) ELECTION IS ATTACHED TO THIS AGREEMENT AS EXHIBIT D AND THE PURCHASER (AND NOT THE COMPANY OR ANY OF ITS AGENTS) SHALL BE
SOLELY RESPONSIBLE FOR APPROPRIATELY FILING SUCH FORM, EVEN IF THE PURCHASER REQUESTS THE COMPANY OR ITS AGENTS TO MAKE THIS FILING ON THE PURCHASER’S BEHALF. 
  

	10.	General Provisions. 

 A. Choice of Law. This Agreement shall be governed by
the internal substantive laws, but not the choice of law rules, of California. 
 B. Integration. This Agreement, including all
exhibits hereto, represents the entire agreement between the parties with respect to the purchase of the Shares by the Purchaser and supersedes and replaces any and all prior written or oral agreements regarding the subject matter of this Agreement
including, but not limited to, any representations made during any interviews, relocation discussions or negotiations whether written or oral. 

C. Notices. Any notice, demand, offer, request or other communication required or permitted to be given by either the Company or
the Purchaser pursuant to the terms of this Agreement shall be in writing and shall be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one business day after being delivered by
facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited with an overnight courier service or (v) four days after being deposited in the U.S. mail, First Class with postage prepaid and return
receipt requested, and addressed to the parties at the addresses provided to the Company (which the Company agrees to disclose to the other parties upon request) or such other address as a party may request by notifying the other in writing. 

  
 10 

 D. Successors. Any successor to the Company (whether direct or indirect and whether
by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this
Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any
successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in this section or which becomes bound by the terms of this Agreement by operation of law. Subject to the restrictions on transfer
set forth in this Agreement, this Agreement shall be binding upon the Purchaser and his or her heirs, executors, administrators, successors and assigns. 

E. Assignment; Transfers. Except as set forth in this Agreement, this Agreement, and any and all rights, duties and obligations
hereunder, shall not be assigned, transferred, delegated or sublicensed by the Purchaser without the prior written consent of the Company. Any attempt by the Purchaser without such consent to assign, transfer, delegate or sublicense any rights,
duties or obligations that arise under this Agreement shall be void. Except as set forth in this Agreement, any transfers in violation of any restriction upon transfer contained in any section of this Agreement shall be void, unless such restriction
is waived in accordance with the terms of this Agreement. 
 F. Waiver. Either party’s failure to enforce any provision of
this Agreement shall not in any way be construed as a waiver of any such provision, nor prevent that party from thereafter enforcing any other provision of this Agreement. The rights granted both parties hereunder are cumulative and shall not
constitute a waiver of either party’s right to assert any other legal remedy available to it. 
 G. Purchaser Investment
Representations and Further Documents. The Purchaser agrees upon request to execute any further documents or instruments necessary or reasonably desirable in the view of the Company to carry out the purposes or intent of this Agreement,
including (but not limited to) the applicable exhibits and attachments to this Agreement. 
 H. Severability. Should any
provision of this Agreement be found to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable to the greatest extent permitted by law. 

I. Rights as Stockholder. Subject to the terms and conditions of this Agreement, the Purchaser shall have all of the rights of a
stockholder of the Company with respect to the Shares from and after the date that the Purchaser delivers a fully executed copy of this Agreement (including the applicable exhibits and attachments to this Agreement) and full payment for the Shares
to the Company, and until such time as the Purchaser disposes of the Shares in accordance with this Agreement. Upon such transfer, the Purchaser shall have no further rights as a holder of the Shares so purchased except (in the case of a transfer to
the Company) the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and the Purchaser shall forthwith cause any certificate(s) evidencing the Shares so purchased to be surrendered to the Company
for transfer or cancellation. 

  
 11 

 J. Adjustment for Stock Split. All references to the number of Shares and the
purchase price of the Shares in this Agreement shall be adjusted to reflect any stock split, stock dividend or other change in the Shares which may be made after the date of this Agreement. 

K. Employment at Will. THE PURCHASER ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THIS AGREEMENT IS EARNED ONLY
BY CONTINUING SERVICE AS A SERVICE PROVIDER AT WILL (AND NOT THROUGH THE ACT OF BEING HIRED OR PURCHASING SHARES HEREUNDER). THE PURCHASER FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING
SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, OR FOR ANY PERIOD AT ALL, AND SHALL NOT INTERFERE WITH THE PURCHASER’S RIGHT OR THE COMPANY’S
RIGHT TO TERMINATE THE PURCHASER’S RELATIONSHIP WITH THE COMPANY AT ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE. 
 L. Arbitration
and Equitable Relief. 
 (1) Arbitration. IN CONSIDERATION OF THE PROMISES IN THIS AGREEMENT, THE PURCHASER AGREES THAT ANY
AND ALL CONTROVERSIES, CLAIMS, OR DISPUTES WITH ANYONE (INCLUDING THE COMPANY AND ANY EMPLOYEE, OFFICER, DIRECTOR, SHAREHOLDER OR BENEFIT PLAN OF THE COMPANY IN THEIR CAPACITY AS SUCH OR OTHERWISE) ARISING OUT OF, RELATING TO, OR RESULTING FROM THIS
AGREEMENT, SHALL BE SUBJECT TO BINDING ARBITRATION UNDER THE ARBITRATION RULES SET FORTH IN CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 1280 THROUGH 1294.2, INCLUDING SECTION 1283.05 (THE “RULES”) AND PURSUANT TO CALIFORNIA
LAW, AND SHALL BE BROUGHT IN THE PURCHASER’S INDIVIDUAL CAPACITY, AND NOT AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR REPRESENTATIVE PROCEEDING. DISPUTES WHICH THE PURCHASER AGREES TO ARBITRATE, AND THEREBY AGREES TO WAIVE ANY
RIGHT TO A TRIAL BY JURY, INCLUDE ANY STATUTORY CLAIMS UNDER STATE OR FEDERAL LAW, INCLUDING, BUT NOT LIMITED TO, CLAIMS UNDER TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, THE AMERICANS WITH DISABILITIES ACT OF 1990, THE AGE DISCRIMINATION IN
EMPLOYMENT ACT OF 1967, THE OLDER WORKERS BENEFIT PROTECTION ACT, THE WORKER ADJUSTMENT AND RETRAINING NOTIFICATION ACT, THE CALIFORNIA FAIR EMPLOYMENT AND HOUSING ACT, THE FAMILY AND MEDICAL LEAVE ACT, THE CALIFORNIA FAMILY RIGHTS ACT, THE
CALIFORNIA LABOR CODE, CLAIMS OF HARASSMENT, DISCRIMINATION OR WRONGFUL TERMINATION AND ANY STATUTORY CLAIMS. THE PURCHASER FURTHER UNDERSTANDS THAT THIS AGREEMENT TO ARBITRATE ALSO APPLIES TO ANY DISPUTES THAT THE COMPANY MAY HAVE WITH THE
PURCHASER. 

  
 12 

 (2) Procedure. THE PURCHASER AGREES THAT ANY ARBITRATION WILL BE ADMINISTERED BY THE
AMERICAN ARBITRATION ASSOCIATION (“AAA”) AND THAT THE NEUTRAL ARBITRATOR WILL BE SELECTED IN A MANNER CONSISTENT WITH ITS NATIONAL RULES FOR THE RESOLUTION OF EMPLOYMENT DISPUTES. THE PURCHASER AGREES THAT THE ARBITRATOR
SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY PARTY TO THE ARBITRATION, INCLUDING MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION AND MOTIONS TO DISMISS AND DEMURRERS, PRIOR TO ANY ARBITRATION HEARING. THE PURCHASER ALSO AGREES THAT THE
ARBITRATOR SHALL HAVE THE POWER TO AWARD ANY REMEDIES, INCLUDING ATTORNEYS’ FEES AND COSTS, AVAILABLE UNDER APPLICABLE LAW. THE PURCHASER UNDERSTANDS THAT THE COMPANY WILL PAY FOR ANY ADMINISTRATIVE OR HEARING FEES CHARGED BY THE ARBITRATOR OR
AAA EXCEPT THAT THE PURCHASER SHALL PAY THE FIRST $125.00 OF ANY FILING FEES ASSOCIATED WITH ANY ARBITRATION THE PURCHASER INITIATES. THE PURCHASER AGREES THAT THE ARBITRATOR SHALL ADMINISTER AND CONDUCT ANY ARBITRATION IN A MANNER CONSISTENT WITH
THE RULES AND THAT TO THE EXTENT THAT THE AAA’S NATIONAL RULES FOR THE RESOLUTION OF EMPLOYMENT DISPUTES CONFLICT WITH THE RULES, THE RULES SHALL TAKE PRECEDENCE. THE PURCHASER AGREES THAT THE DECISION OF THE ARBITRATOR SHALL BE IN WRITING.

 (3) Remedy. EXCEPT AS PROVIDED BY THE RULES AND THIS AGREEMENT, ARBITRATION SHALL BE THE SOLE, EXCLUSIVE AND FINAL REMEDY FOR ANY
DISPUTE BETWEEN THE PURCHASER AND THE COMPANY. ACCORDINGLY, EXCEPT AS PROVIDED FOR BY THE RULES AND THIS AGREEMENT, NEITHER THE PURCHASER NOR THE COMPANY WILL BE PERMITTED TO PURSUE COURT ACTION REGARDING CLAIMS THAT ARE SUBJECT TO ARBITRATION.
NOTWITHSTANDING, THE ARBITRATOR WILL NOT HAVE THE AUTHORITY TO DISREGARD OR REFUSE TO ENFORCE ANY LAWFUL COMPANY POLICY, AND THE ARBITRATOR SHALL NOT ORDER OR REQUIRE THE COMPANY TO ADOPT A POLICY NOT OTHERWISE REQUIRED BY LAW WHICH THE COMPANY HAS
NOT ADOPTED. 
 (4) Availability of Injunctive Relief. BOTH PARTIES AGREE THAT ANY PARTY MAY PETITION A COURT FOR INJUNCTIVE RELIEF AS
PERMITTED BY THE RULES INCLUDING, BUT NOT LIMITED TO, WHERE EITHER PARTY ALLEGES OR CLAIMS A VIOLATION OF ANY CONFIDENTIAL INFORMATION OR INVENTION ASSIGNMENT AGREEMENT BETWEEN THE PURCHASER AND THE COMPANY OR ANY OTHER AGREEMENT REGARDING TRADE
SECRETS, CONFIDENTIAL INFORMATION, NONSOLICITATION OR LABOR CODE §2870. BOTH PARTIES UNDERSTAND THAT ANY BREACH OR THREATENED BREACH OF SUCH AN AGREEMENT WILL CAUSE IRREPARABLE INJURY AND THAT MONEY DAMAGES WILL NOT PROVIDE AN ADEQUATE REMEDY
THEREFOR AND BOTH PARTIES HEREBY CONSENT TO THE ISSUANCE OF AN INJUNCTION. IN THE EVENT EITHER PARTY SEEKS INJUNCTIVE RELIEF, THE PREVAILING PARTY SHALL BE ENTITLED TO RECOVER REASONABLE COSTS AND ATTORNEYS’ FEES. 

  
 13 

 (5) Administrative Relief. THE PURCHASER UNDERSTANDS THAT THIS AGREEMENT DOES NOT PROHIBIT
THE PURCHASER FROM PURSUING AN ADMINISTRATIVE CLAIM WITH A LOCAL, STATE OR FEDERAL ADMINISTRATIVE BODY SUCH AS THE DEPARTMENT OF FAIR EMPLOYMENT AND HOUSING, THE EQUAL EMPLOYMENT OPPORTUNITY COMMISSION OR THE WORKERS’ COMPENSATION BOARD. THIS
AGREEMENT DOES, HOWEVER, PRECLUDE THE PURCHASER FROM PURSUING COURT ACTION REGARDING ANY SUCH CLAIM. 
 (6) Voluntary Nature of
Agreement. THE PURCHASER ACKNOWLEDGES AND AGREES THAT THE PURCHASER IS EXECUTING THIS AGREEMENT VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE BY THE COMPANY OR ANYONE ELSE. THE PURCHASER FURTHER ACKNOWLEDGES AND AGREES THAT THE PURCHASER
HAS CAREFULLY READ THIS AGREEMENT AND THAT THE PURCHASER HAS ASKED ANY QUESTIONS NEEDED FOR THE PURCHASER TO UNDERSTAND THE TERMS, CONSEQUENCES AND BINDING EFFECT OF THIS AGREEMENT AND FULLY UNDERSTANDS IT, INCLUDING THAT THE PURCHASER IS
WAIVING THE PURCHASER’S RIGHT TO A JURY TRIAL. FINALLY, THE PURCHASER AGREES THAT THE PURCHASER HAS BEEN PROVIDED AN OPPORTUNITY TO SEEK THE ADVICE OF AN ATTORNEY OF THE PURCHASER’S CHOICE BEFORE SIGNING THIS AGREEMENT. 

M. Reliance on Counsel and Advisors. The Purchaser acknowledges that Latham & Watkins LLP, is representing only the
Company in this transaction. The Purchaser acknowledges that he has had the opportunity to review this Agreement, including all attachments hereto, and the transactions contemplated by this Agreement with his or her own legal counsel, tax advisors
and other advisors. The Purchaser is relying solely on his own counsel and advisors and not on any statements or representations of the Company or its agents for legal or other advice with respect to this investment or the transactions contemplated
by this Agreement. 
 N. Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed
an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages shall be binding originals. 

(signature page follows) 

  
 14 

 The parties represent that they have read this Agreement in its entirety, have had an opportunity
to obtain the advice of counsel prior to executing this Agreement and fully understand this Agreement. The Purchaser agrees to notify the Company of any change in his or her address below. 

 

	
	MATTHEW DAVIDSON
	
	 /s/ Matthew Davidson

	
	XXX
	
	VERRICA PHARMACEUTICALS INC.
	
	 /s/ Matthew Davidson

	 Matthew Davidson
 President and Chief Executive
Officer

	
	XXX

 [Signature Page to Amended and Restated Restricted Stock Purchase Agreement] 

 Exhibit A 

INVESTMENT REPRESENTATION STATEMENT 
  

					
	PURCHASER	  	:	  	Matthew Davidson
			
	COMPANY	  	:	  	Verrica Pharmaceuticals Inc.
			
	SECURITY	  	:	  	Common Stock
			
	AMOUNT	  	:	  	6,000,000 shares
			
	DATE	  	:	  	August 8, 2013

 In connection with the purchase of the above-listed shares, I, the undersigned purchaser, represent to the
Company as follows: 
 1. The Company may rely on these representations. I understand that the Company’s sale of the
shares to me has not been registered under the Securities Act of 1933, as amended (the “Securities Act”) because the Company believes, relying in part on my representations in this document, that an exemption from such
registration requirement is available for such sale. I understand that the availability of this exemption depends upon the representations I am making to the Company in this document being true and correct. 

2. I am purchasing for investment. I am purchasing the shares solely for investment purposes, and not for further distribution.
My entire legal and beneficial ownership interest in the shares is being purchased and shall be held solely for my account, except to the extent I intend to hold the shares jointly with my spouse. I am not a party to, and do not presently intend to
enter into, any contract or other arrangement with any other person or entity involving the resale, transfer, grant of participation with respect to or other distribution of any of the shares. My investment intent is not limited to my present
intention to hold the shares for the minimum capital gains period specified under any applicable tax law, for a deferred sale, for a specified increase or decrease in the market price of the shares, or for any other fixed period in the future. 

3. I can protect my own interests. I can properly evaluate the merits and risks of an investment in the shares and can protect my
own interests in this regard, whether by reason of my own business and financial expertise, the business and financial expertise of certain professional advisors unaffiliated with the Company with whom I have consulted, or my preexisting business or
personal relationship with the Company or any of its officers, directors or controlling persons. 
 4. I am informed about the
Company. I am sufficiently aware of the Company’s business affairs and financial condition to reach an informed and knowledgeable decision to acquire the shares. I have had opportunity to discuss the plans, operations and financial
condition of the Company with its officers, directors or controlling persons, and have received all information I deem appropriate for assessing the risk of an investment in the shares. 

  
 1 

 5. I recognize my economic risk. I realize that the purchase of the shares involves
a high degree of risk, and that the Company’s future prospects are uncertain. I am able to hold the shares indefinitely if required, and am able to bear the loss of my entire investment in the shares. 

6. I know that the shares are restricted securities. I understand that the shares are “restricted securities” in that
the Company’s sale of the shares to me has not been registered under the Securities Act in reliance upon an exemption for non-public offerings. In this regard, I also understand and agree that: 

A. I must hold the shares indefinitely, unless any subsequent proposed resale by me is registered under the Securities Act, or unless an
exemption from registration is otherwise available (such as Rule 144); 
 B. the Company is under no obligation to register any subsequent
proposed resale of the shares by me; and 
 C. the certificate evidencing the shares will be imprinted with a legend which prohibits the
transfer of the shares unless such transfer is registered or such registration is not required in the opinion of counsel for the Company. 

7. I am familiar with Rule 144. I am familiar with Rule 144 adopted under the Securities Act, which in some circumstances permits
limited public resales of “restricted securities” like the shares acquired from an issuer in a non-public offering. I understand that my ability to sell the shares under Rule 144 in the future is
uncertain, and may depend upon, among other things: (i)the availability of certain current public information about the Company; (ii) the resale occurring more than a specified period after my purchase and full payment (within the meaning of
Rule 144) for the shares; and (iii) if I am an affiliate of the Company (A) the sale being made in an unsolicited “broker’s transaction”, transactions directly with a market maker or riskless principal transactions, as those
terms are defined under the Securities Exchange Act of 1934, as amended, (B) the amount of shares being sold during any three-month period not exceeding the specified limitations stated in Rule 144, and (C) timely filing of a notice of
proposed sale on Form 144, if applicable. 
 8. I know that Rule 144 may never be available. I understand that the requirements
of Rule 144 may never be met, and that the shares may never be saleable under the rule. I further understand that at the time I wish to sell the shares, there may be no public market for the Company’s stock upon which to make such a sale, or
the current public information requirements of Rule 144 may not be satisfied, either of which may preclude me from selling the shares under Rule 144 even if the relevant holding period had been satisfied. 

9. I know that I am subject to further restrictions on resale. I understand that in the event Rule 144 is not available to me,
any future proposed sale of any of the shares by me will not be possible without prior registration under the Securities Act, compliance with some other registration exemption (which may or may not be available), or each of the following:
(i) my written notice to the Company containing detailed information regarding the proposed sale, (ii) my providing an opinion of my counsel to the effect that such sale will not require registration, and (iii) the Company notifying
me in writing that its counsel concurs in such opinion. I 

  
 2 

 
understand that neither the Company nor its counsel is obligated to provide me with any such opinion. I understand that although Rule 144 is not exclusive, the Staff of the SEC has stated that
persons proposing to sell private placement securities other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and
that such persons and their respective brokers who participate in such transactions do so at their own risk. 
 10. I know that I may
have tax liability due to the uncertain value of the shares. I understand that the board of directors believes its valuation of the shares represents a fair appraisal of their worth, but that it remains possible that, with the benefit of
hindsight, the Internal Revenue Service may successfully assert that the value of the shares on the date of my purchase is substantially greater than the Board’s appraisal. I understand that any additional value ascribed to the shares by such
an IRS determination will constitute ordinary income to me as of the purchase date, and that any additional taxes and interest due as a result will be my sole responsibility payable only by me, and that the Company need not and will not reimburse me
for that tax liability. 
 11. Residence. The address of my principal residence is set forth on the signature page below. 

By signing below, I acknowledge my agreement with each of the statements contained in this Investment Representation Statement as of the date
first set forth above, and my intent for the Company to rely on such statements in issuing the shares to me. 
  

	
	  

	Purchaser’s Signature
	
	  

	Print Name

 Address of Purchaser’s principal residence: 

XXX 

  
 3 

 Exhibit B 

STOCK POWER AND ASSIGNMENT 

SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED and pursuant to that certain Amended and Restated Restricted Stock Purchase Agreement dated as of December 1, 2015,
the undersigned hereby sells, assigns and transfers
unto                                    
,                                       
                 
(                             ) shares of Common Stock of Verrica Pharmaceuticals Inc., a Delaware
corporation, standing in the undersigned’s name on the books of said corporation represented by certificate number                    
delivered herewith, and does hereby irrevocably constitute and appoint the Corporate Secretary of Verrica Pharmaceuticals Inc. as attorney-in-fact, with full power
of substitution, to transfer said stock on the books of said corporation. 
 Dated: 

 

	
	  

	(Signature)
	
	  

	(Print Name)
	
	  

	(Spouse’s Signature, if any)
	
	  

	(Print Spouse’s Name)

 This Assignment Separate From Certificate was executed in conjunction with the terms of an Amended and
Restated Restricted Stock Purchase Agreement between the above assignor and the above corporation, dated as of [                ], 2015. 

Instruction: Please do not fill in any blanks other than the signature and name lines. 

 Exhibit C 

AMENDED AND RESTATED JOINT ESCROW INSTRUCTIONS 

[                ], 2015 

Verrica Pharmaceuticals Inc. 
 918 McCue Avenue 

San Carlos, CA 94070 
 Attn: Corporate Secretary 

Dear Secretary: 
 As Escrow Agent for both
Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Matthew Davidson (the “Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant to
the terms of that certain Amended and Restated Restricted Stock Purchase Agreement (the “Agreement”), dated as of
                    , 2013, to which a copy of these Amended and Restated Joint Escrow Instructions is attached, in accordance with the
following instructions: 
 1. In the event that the Company and/or any assignee of the Company (referred to collectively for convenience
herein as the “Company”) exercises the Repurchase Option set forth in the Agreement, the Company shall give to the Purchaser and you a written notice specifying the number of shares of stock to be purchased, the purchase
price, and the time for a closing hereunder at the principal office of the Company. The Purchaser and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said
notice. 
 2. At the closing, you are directed (a) to date the stock assignments necessary for the transfer in question, (b) to
fill in the number of shares being transferred, and (c) to deliver same, together with the certificate evidencing the shares of stock to be transferred, to the Company against the simultaneous delivery to you of the purchase price (by check or
such other form of consideration mutually agreed to by the parties) for the number of shares of stock being purchased pursuant to the exercise of the Repurchase Option. 

3. The Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by you hereunder
and any additions and substitutions to said shares as defined in the Agreement. The Purchaser does hereby irrevocably constitute and appoint you as his or her
attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities
negotiable and to complete any transaction herein contemplated. Subject to the provisions of this paragraph 3, the Purchaser shall exercise all rights and privileges of a stockholder of the Company while the stock is held by you. 

4. Upon written request of the Purchaser after each successive one-year period from the date of the
Agreement, unless the Repurchase Option has been exercised, you will deliver to the Purchaser a certificate or certificates representing so many shares of stock remaining in escrow as are not then subject to the Repurchase Option. 

 5. If at the time of termination of this escrow you should have in your possession any documents,
securities, or other property belonging to the Purchaser, you shall deliver all of same to the Purchaser and shall be discharged of all further obligations hereunder. 

6. Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 

7. You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in
relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as
Escrow Agent or as attorney-in-fact for the Purchaser while acting in good faith and in the exercise of your own good judgment, and any act done or omitted by you
pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith. 
 8. The Company and the Purchaser hereby
jointly and severally expressly agree to indemnify and hold harmless you and your designees against any and all claims, losses, liabilities, damages, deficiencies, costs and expenses, including reasonable attorneys’ fees and expenses of
investigation and defense incurred or suffered by you and your designees, directly or indirectly, as a result of any of your actions or omissions or those of your designees while acting in good faith and in the exercise of your judgment under the
Agreement, these Amended and Restated Joint Escrow Instructions, exhibits hereto or written instructions from the Company or the Purchaser hereunder. 

9. You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or
corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree, you shall not
be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have
been entered without jurisdiction. 
 10. You shall not be liable in any respect on account of the identity, authorities or rights of the
parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. 

11. You shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with
your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. The Company shall reimburse you for any such disbursements. 

12. Your responsibilities as Escrow Agent hereunder shall terminate if you shall resign by written notice to each party. In the event of any
such termination, the Company shall appoint a successor Escrow Agent. 

 13. If you reasonably require other or further instruments in connection with these Joint Escrow
Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments. 
 14. It is
understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to
anyone all or any part of said securities until such disputes shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal
has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings. 
 15.
Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or four days following deposit in the United States Post Office, by registered or certified mail with postage and fees
prepaid and return receipt requested, addressed to each of the other parties thereunto entitled at the following addresses, or at such other addresses as a party may designate by written notice to each of the other parties hereto. 

 

			
	COMPANY:	  	Verrica Pharmaceuticals Inc.
		  	XXX
		  	Attn: President
		
	PURCHASER:	  	Matthew Davidson
		  	XXX
		
	ESCROW AGENT:	  	Corporate Secretary
		  	XXX

 16. By signing these Amended and Restated Joint Escrow Instructions, you become a party hereto only for the
purpose of said Amended and Restated Joint Escrow Instructions; you do not become a party to the Agreement. 
 17. This instrument shall be
binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns. 

 
	
	Very truly yours,
	
	VERRICA PHARMACEUTICALS INC.
	
	By:
                                         
                                 
	
	Print Name:
                                         
                   
	
	Print Title:
                                         
                     
	
	PURCHASER:
	
	MATTHEW DAVIDSON
	
	  

	(Signature)

  

	
	ESCROW AGENT:
	
	  
 Allison Davidson, Corporate
Secretary

 (Signature page to Joint Escrow Instructions) 

 IF YOU WISH TO MAKE A SECTION 83(B) ELECTION, THE FILING OF 

SUCH ELECTION IS YOUR RESPONSIBILITY. 

THE FORM FOR MAKING THIS SECTION 83(B) ELECTION IS 

ATTACHED TO THIS AGREEMENT AS EXHIBIT D. 

YOU MUST FILE THIS FORM WITHIN 30 DAYS OF PURCHASING THE SHARES. 

YOU (AND NOT THE COMPANY OR ANY OF ITS AGENTS) SHALL BE 

SOLELY RESPONSIBLE FOR FILING SUCH FORM WITH THE IRS, 

EVEN IF YOU REQUEST THE COMPANY OR ITS AGENTS TO MAKE 

THIS FILING ON YOUR BEHALF AND EVEN IF THE COMPANY OR ITS 

AGENTS HAVE PREVIOUSLY MADE THIS FILING ON YOUR BEHALF. 

The election should be filed by mailing a signed election form by certified mail, return receipt 

requested to the IRS Service Center where you file your tax returns. See <www.irs.gov> 

 Exhibit D 

ELECTION UNDER SECTION 83(b) OF THE 

INTERNAL REVENUE CODE OF 1986, AS AMENDED 

The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in his or
her gross income for the current taxable year, the amount of any compensation taxable to him or her in connection with his or her receipt of the property described below: 

1. The name, address and taxpayer identification number of the undersigned are as follows: 

 

					
		 	NAME OF TAXPAYER: Matthew Davidson	  	SPOUSE: Allison Davidson
		
		 	TAXPAYER’S ADDRESS: XXX
			
		 	TAXPAYER ID #:	  	SPOUSE’S ID #:

 2. The property with respect to which the election is made is described as follows: 6,000,000 shares (the
“Shares”) of the Common Stock of Verrica Pharmaceuticals Inc. (the “Company”). 
 3. The date
on which the property was transferred is: August 8, 2013. 
 4. The taxable year for which the election is made is: 2013. 

5. The property is subject to the following restrictions: The Shares may be repurchased by the Company, or its assignee, upon the occurrence of
certain events. This right lapses with regard to a portion of the Shares over time. 
 6. The fair market value at the time of transfer,
determined without regard to any restriction other than a restriction which by its terms will never lapse, of such property is: $600.00. 

7. The amount, if any, paid for such property: $600.00. 

The undersigned has submitted a copy of this statement to the person for whom the services were performed in connection with the
undersigned’s receipt of the above-described property. The transferee of such property is the person performing the services in connection with the transfer of said property. 

 The undersigned understand(s) that the foregoing election may not be revoked except with the
consent of the Commissioner. 
  

			
	Dated: August 8, 2013	  	  

		  	Matthew Davidson, Taxpayer
	
	The undersigned spouse of taxpayer joins in this election.
		  	  

	Dated: August 8, 2013	  	Allison Davidson, Spouse of Taxpayer

 Exhibit E 

SPOUSAL CONSENT 
 I,
Allison Davidson, spouse of Matthew Davidson, have read and approve of the foregoing Amended and Restated Restricted Stock Purchase Agreement, dated as of December 1, 2015, together with all exhibits and attachments thereto (collectively, the
“Agreement”), by and between my spouse and Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”). In consideration of the Company’s granting of the right to Matthew Davidson to
purchase 5,819,783 shares of Common Stock of the Company as set forth in the Agreement and after giving effect to the Repurchase Closing (as defined in the Agreement), I hereby appoint Matthew Davidson as my attorney-in-fact in respect to the exercise or waiver of any rights under the Agreement, and agree to be bound by the provisions of the Agreement insofar as I may have any rights in said Agreement or any
shares issued pursuant thereto under the community property laws of the State of California, or under similar laws relating to marital property in effect in the state of our residence as of the date of the signing of the foregoing Agreement. 

Dated:                         
   , 2015 
  

	
	“Spouse of Purchaser”
	
	  

	(Signature)
	
	  

	(Print Name)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]